Notice of H1 Results

RNS Number : 2819F

IXICO plc

16 May 2017

 

16 May 2017

IXICO plc

("IXICO" or the "Company")

Notice of Interim Results

IXICO, the brain health company, will announce its interim results for the six months ended 31 March 2017 on Monday 22 May 2017.

For further information please contact:

IXICO plc Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: [phone]

About IXICO

Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global Pharmaceutical industry to select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.  Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis and Parkinson's and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant patient clinical data to enable sponsors to make rapid, better informed decisions.

IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes

More information is available on www.ixico.com

 

END

 

 

NOREAPSKFSXXEEF